ABC Arbitrage SA Purchases Shares of 186,161 Fresenius Medical Care AG (NYSE:FMS)

ABC Arbitrage SA purchased a new stake in Fresenius Medical Care AG (NYSE:FMS) during the 4th quarter, HoldingsChannel reports. The fund purchased 186,161 shares of the company’s stock, valued at approximately $4,215,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Verition Fund Management LLC purchased a new stake in shares of Fresenius Medical Care in the 3rd quarter valued at about $237,000. JPMorgan Chase & Co. raised its holdings in shares of Fresenius Medical Care by 18.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock valued at $211,000 after acquiring an additional 1,528 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Fresenius Medical Care by 11.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock valued at $472,000 after acquiring an additional 2,233 shares in the last quarter. Quantinno Capital Management LP raised its holdings in shares of Fresenius Medical Care by 78.9% in the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after acquiring an additional 48,554 shares in the last quarter. Finally, MML Investors Services LLC raised its holdings in shares of Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock valued at $320,000 after acquiring an additional 753 shares in the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Price Performance

FMS opened at $23.46 on Friday. The stock’s 50 day simple moving average is $23.47 and its 200 day simple moving average is $21.49. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $25.25. The firm has a market cap of $13.76 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 0.80 and a beta of 0.93.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on FMS shares. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial increased their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Finally, Berenberg Bank started coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective on the stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.